Imodiumlingual

Loperamide Hydrochloride, the active ingredient in Imodiumlingual, is a peripheral μ‑opioid receptor agonist presented as an oral dosage form for oral use. It reduces intestinal motility and secretion, helping to control acute and chronic diarrhea in adults and children when appropriate.

GNH USA supplies Imodiumlingual as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑supported distribution across EU and global markets. Customers benefit from reliable supply chains, comprehensive documentation, and responsive technical support.

Loperamide Hydrochloride is used to manage conditions involving excessive intestinal motility and fluid loss.

Acute diarrhea: reduces stool frequency and liquidity in short‑term diarrheal episodes. Chronic diarrhea: helps maintain stool consistency in long‑term diarrheal disorders. Irritable bowel syndrome with diarrhea: alleviates diarrheal symptoms associated with IBS‑D.

Loperamide Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Constipation: hard stools or reduced bowel movements. - Abdominal cramps: mild to moderate discomfort in the abdomen. - Nausea: feeling of queasiness or urge to vomit. - Dizziness: light‑headed sensation, especially after first dose.

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction: abdominal pain, vomiting, inability to pass gas. - Toxic megacolon: rapid abdominal distension, fever, systemic toxicity. - Cardiac arrhythmias: irregular heartbeat, palpitations, especially with high doses or drug interactions.

When using Loperamide Hydrochloride, certain precautions should be observed to ensure safe and effective therapy.

- Assess underlying cause: confirm that diarrhea is not due to infection before initiating therapy. - Use in children: limit use to age‑appropriate dosing and avoid in infants under two years. - Monitor dehydration: ensure adequate fluid and electrolyte replacement during treatment. - Avoid in high‑risk patients: patients with severe hepatic impairment or known intestinal obstruction should not use. - Review concomitant medications: check for drugs that may increase cardiac risk or affect metabolism. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Loperamide Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - P‑glycoprotein inhibitors (e.g., quinidine, ketoconazole): may increase systemic exposure and risk of cardiac toxicity. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can raise plasma levels and precipitate serious adverse events. - Opioid analgesics: additive central opioid effects are unlikely but may increase constipation.

Moderate Interactions (Monitor Closely): - Antidiarrheal agents (e.g., bismuth subsalicylate): may reduce overall effectiveness. - Anticholinergic drugs: may enhance anticholinergic burden, leading to dry mouth or urinary retention. - Electrolyte‑altering medications (e.g., diuretics): monitor for dehydration and electrolyte imbalance.